Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers,
β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both
diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an
anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized,
controlled trial.
Phase:
N/A
Details
Lead Sponsor:
Emory University
Collaborators:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc. National Center for Research Resources (NCRR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)